Recordati : Proposta FIMEI S.p.A. su integrazione Consiglio di Amministrazione (punto 2 all’ordine del giorno dell'Assemblea)

Comunicazione ex art 23 del Provvedimento congiunto CONSOB/Banca d'Italia del 22 febbraio 2008 e successive modifiche e integrazioni (c.d. " Provvedimento Post Trading")

Intermediario che effettua la comunicazione ABI (conto MT) 63111

CAB 01600

Ultimo intermediario, se diverso dal precedente, o Intermediario cedente in caso di trasferimento tra

intermediari			ABI	CAB
Data rilascio 15 aprile 2020
N. prog. annuo		Codice Cliente
0035/2020		3101632
A richiesta di	__________________		FIMEI SPA
				VIA DEL VECCHIO POLITECNICO 9
				20148 MILANO MI
				Part. IVA : 10042010156

Luogo e data di nascita

La presente comunicazione, con efficacia sino al 05/05/2020 attesta la partecipazione al sistema di gestione accentrata del nominativo sopra indicato con i seguenti strumenti finanziari:

codice	descrizione strumenti finanziari	quantità
IT0003828271	RECORDATI ORD	108.368.721,00

Su detti strumenti finanziari risultano le seguenti annotazioni:

I titoli sono bloccati fino a data efficacia certificazione

La presente certificazione viene rilasciata per l'esercizio del seguente diritto:

Certificazione di possesso per la nomina dei membri del CDA di RECORDATI

UNIONE DI BANCHE ITALIANE SPA

Unione di Banche Italiane S.p.A.	Aderente al Fondo Interbancario di Tutela	Cap.Soc. Euro 2.843.177.160,24 (al 23/10/2017)
Sede Legale e Direzione Generale:	dei Depositi e al Fondo Nazionale di Garanzia	Abi 03111.2, Albo delle Banche n. 5678, facente
Piazza Vittorio Veneto, 8	Appartenente al Gruppo Iva UBI con partita	parte del Gruppo Bancario Unione di Banche Italiane
24122 BERGAMO (BG)	IVA 04334690163	Albo dei Gruppi Bancari n. 3111.2
Sedi operative: Brescia e Bergamo	Codice Fiscale e Registro Imprese di Bergamo	Capogruppo del Gruppo Bancario
www.ubibanca.com	n. 03053920165	Unione di Banche Italiane.
[e-mail]
[e-mail]

FRANCESCO BALESTRIERI

Email: [e-mail]

Born on 22 January 1969

He graduated in Business Administration in 1993 at the Ca' Foscari University of Venice.

In 1993 he joined Alcon (formerly CIBA Vision), a division of Novartis, which operates in the eye care sector and develops and markets contact lenses, eye care products, ophthalmic and surgical products, with the position of Head Business Planning and Analysis Italy until 1995, then Project Manager from 1995 to 1996, Head Finance Europe and APAC from 1996 to 1998, Global Head of Financial Planning and Control from 1998 to 2000, General Manager CE and ME from 2000 to 2001, Commercial Head Europe from 2002 to 2005, General Manager DACH from 2005 to 2007, up to the position of President USA, Canada and Latin America from 2008 to 2011, where, as regional manager for USA, Canada and Latin America, he developed and implemented a new strategy for the U.S. market that brings the business in line with growth aspirations.

In 2011 he joined Sandoz, a division of Novartis, which operates in the sector of generic and special medicines, hospital products, biopharmaceuticals and OTC, here he held various positions, always reporting to the CEO of Sandoz, in particular he was President Asia-Pacific until 2013, then President CEE and Global Head OTC until 2015, President CEEMEA until 2017 and from 2018 to 2019 President Europe where, as a member of the Global Executive Committee, he was in charge of the region's strategic agenda, preparation and launch of biosimilar products and portfolio review to redefine the market perimeter and ensure investments in line with growth aspirations. In 2019 he assumes the role of ad interimCEO of Sandoz S.p.A., at the Munich office, until August 2019.

During his career he has also held the position of director at Sandoz S.p.A. and Mipharm S.p.a..

He currently holds the position of sole director of Full Skin S.r.l..

April 2020

GUIDO GUIDI

Email: [e-mail]

Data di nascita: 27 marzo 1953

Si laurea in medicina, cum laude, nel 1979 presso l'Università degli Studi di Milano, con la specializzazione, presso la medesima università, prima in immunologia e allergologia, conseguita nel 1984, e successivamente in reumatologia, conseguita nel 1989.

Medico abilitato dal 1980, ricopre la qualifica di Medical Advisorprima in Smith Kline & French Italia dal 1981 al 1982 e poi, dal 1983 al 1985 in Roussel UCLAF Italia, successivamente Medical Directordal 1986 al 1989 in Sharper Italia (Roussel UCLAF Group).

In Sandoz Italia dal 1990, fino al 1991 come responsabile dell'area immunologia e trapianti e dal 1992 al 2000 a capo della unità Specialty Products.

Dal 2000 in Novartis si occupa prima dell'unità oncologia Southern Europe e dal 2002 al 2012 è, presso la sede di Milano, a capo dell'Head of Oncology, Europedove ha guidato la commercializzazione di diversi prodotti oncologici e ha svolto un ruolo chiave in diverse operazioni di partnership in qualità di membro Novartis Deal Commitee. Da dicembre 2012 a febbraio 2017, presso la sede svizzera di Basilea, gli viene affidato l'incarico di Head of Pharma, Europe, qui si occupa della commercializzazione di diversi prodotti chiave, coordina operazioni e supervisiona uno staff di oltre 7.000 dipendenti che opera in più di 50 paesi, tra cui Russia e Israele.

Nel frattempo frequenta corsi di business a Losanna nel 2000 e dal 2003 al 2015 a Boston (USA) presso Harvard University.

Nel corso della sua carriera, ha inoltre ricoperto il ruolo di presidente del consiglio di amministrazione di Novartis Italy, Novartis Spain, Novartis Nordics and Novartis UK, è stato membro del Novartis Pharma Executive Committee(PEC), e presidente del Novartis European Executive Committee(EEC), nonchè membro del Novartis Portfolio Management Board, R&D Oncology and Pharmae del EFPIA Executive Committee. È stato insignito dei premi Novartis CEO Excellence Awardnel 2006 e di Novartis CEO Talent Development Awardnel 2008.

Attualmente senior advisorpresso Boston Consulting Group e teaching professor & coordinatordi Medicina Farmaceutica (organizzato da Università degli Studi di Milano e Istituto Mario Negri), ricopre le cariche di (i) foundere presidente del consiglio di amministrazione di AuroraTT S.r.l., (ii) membro del consiglio di amministrazione di Aurora Science S.r.l., Philogen S.p.A., Genenta Science S.r.l. e Tethis S.p.A., (iii) consigliere delegato di Geleven S.r.l., (iv) membro del consiglio di amministrazione e SAB memberdi Zambon S.p.A., (v) SAB membere consulente di Italfarmaco S.p.A..

Aprile 2020

GUIDO GUIDI

Email: [e-mail]

Born on 27 March 1953

He graduated in medicine, cum laude, in 1979 at the University of Milan, with a specialization, at the same university, first in immunology and allergology, achieved in 1984, and then in rheumatology, achieved in 1989.

Medical doctor since 1980, he was Medical Advisor first in Smith Kline & French Italia from 1981 to 1982 and then, from 1983 to 1985 in Roussel UCLAF Italia, then Medical Director from 1986 to 1989 in Sharper Italia (Roussel UCLAF Group).

In Sandoz Italy since 1990, until 1991 as head of the immunology and transplantation area and from 1992 to 2000 as head of the Specialty Products unit.

Since 2000 he has been in charge of the Southern Europe oncology unit at Novartis and from 2002 to 2012 he was head of the Head of Oncology, Europe at the Milan office where he led the marketing of several oncology products and played a key role in several partnership operations as a Novartis Deal Committee member. From December 2012 to February 2017, at the Swiss headquarters in Basel, he was appointed Head of Pharma, Europe, where he leads the marketing of several key products, coordinates operations and supervises a staff of over 7,000 employees working in more than 50 countries, including Russia and Israel.

Meanwhile he attended business courses in Lausanne in 2000 and from 2003 to 2015 in Boston (USA) at Harvard University.

Throughout his career, he has also been Chairman of the Board of Directors of Novartis Italy, Novartis Spain, Novartis Nordics and Novartis UK, he was a member of the Novartis Pharma Executive Committee (PEC), and Chairman of the Novartis European Executive Committee (EEC), as well as a member of the Novartis Portfolio Management Board, R&D Oncology and Pharma and the EFPIA Executive Committee. He was awarded the Novartis CEO Excellence Award in 2006 and the Novartis CEO Talent Development Award in 2008.

Currently senior advisor at Boston Consulting Group and teaching professor & coordinator of Medicina Farmaceutica(organized by Università degli Studi di Milanoand Istituto Mario Negri), he holds the positions of (i) founder and chairman of the board of directors of AuroraTT S.r.l., (ii) member of the board of directors of Aurora Science S.r.l., Philogen S.p.A., Genenta Science S.r.l. and Tethis S.p.A., (iii) managing director of Geleven S.r.l., (iv) member of the board of directors and SAB member of Zambon S.p.A., (v) SAB member and consultant of Italfarmaco S.p.A..

April 2020

PIERGIORGIO PELUSO

Address: via Adda 53, 00198 Rome

Email: [e-mail]

Born on 25 March 1968

Diploma in humanities, degree in "Economics and Social Sciences (D.E.S.)" from Università Commerciale L. Bocconi, with a specialization in Finance, obtained in 1992, and an experience in Arthur Andersen, he joined Mediobanca S.p.A. in the Participations and Special Affairs Service, dealing with mergers, acquisitions and financial restructuring.

In 1998 he worked at Credit Suisse First Boston in London on mergers, acquisitions and capital market transactions in the financial institutions (banking and insurance) and utilities area.

In 2002 he joined Medio Credito Centrale S.p.A. (Capitalia Group), as Central Director of the Advisory Area, and subsequently assumed direct responsibility for the Corporate Division of the Capitalia Group with the title of Central Director and member of the Executive Committee of the banking group. During the years of his management, he was actively involved in the Capitalia Group's recovery plan. In 2007, following the merger between Capitalia S.p.A. and UniCredit Group S.p.A., he was confirmed as Head of Investment Banking in Italy and, subsequently, Managing Director of the corporate bank of the UniCredit Group (UniCredit Corporate Banking S.p.A.) and Head for Italy of the Corporate & Investment Banking Division of the banking group.

From 2011 to September 2012 he was General Manager of Fondiaria-SAI S.p.A., working on the relaunch plan of the insurance group and the subsequent integration with the Unipol group.

From September 2012 to June 2019 he was Telecom Italia's CFO, with responsibilities of various kinds in the areas of: planning and control, transformation office, purchasing, real estate and logistics, finance and investments, accounting and financial, tax, mergers and acquisitions and risk management; participation in road shows and meetings with investors; regular attendance in Telecom Italia's Board of Directors and the Internal Control Committee.

During his career, he has also held the position of Director in several companies, including Banco di Sicilia S.p.A., Edison S.p.A., Gemina S.p.A., Aeroporti di Roma S.p.A., Milano Assicurazioni S.p.A., Fondazione Telecom Italia, Telecom Italia Media S.p.A. and Telecom Argentina S.A. (Argentina).

Since January 2020 he holds the position of member of the Board of Directors of Sacertis S.r.l., a startup that deals with the monitoring of infrastructures and diagnostics for risk assessment.

April, 2020

GIORGIO DE PALMA

Email: [e-mail]

Data di nascita: 28 agosto 1974

Nato a Milano il 28 agosto 1974, ha conseguito una laurea cum laudein Ingegneria Nucleare presso il Politecnico di Milano ed un Diplôme d'Ingénieur presso l'École Centrale de Paris.

Ha cominciato la sua carriera presso Morgan Stanley, ove ha lavorato per oltre quattro anni nel team di M&A.

Nel 2005 è entrato in CVC Capital Partners, ove ricopre attualmente il ruolo di Managing Director.

Attualmente ricopre le seguenti cariche: (i) presidente del Consiglio di Amministrazione di Arzignanese S.r.l., (ii) consigliere di amministrazione di Conceria Pasubio S.p.A., Sisal Group S.p.A., Sisal S.p.A e (iii) amministratore unico di Donizetti Holdings S.r.l.

Aprile 2020

GIORGIO DE PALMA

Email: [e-mail]

Born on 28 August 1974

Giorgio De Palma was born in Milan on 28 August 1974, he earned a summa cum laudedegree in nuclear engineering from the Politecnico di Milano and an engineering degree from the École Centrale de Paris.

He began his career at Morgan Stanley, where he worked for more than four years in the M&A team.

In 2005, he joined CVC Capital Partners, where he currently holds the position of senior managing director.

Mr. De Palma currently holds the following offices: (i) Chairman of the Board of Directors of Arzignanese S.r.l., (ii) member of the Board of Directors of Conceria Pasubio S.p.A., Sisal Group S.p.A., Sisal S.p.A. and (iii) sole director of Donizetti Holdings S.r.l.

April 2020